180 Life Sciences Corp. (ATNF)
ATNF Stock Price Chart
Explore 180 Life Sciences Corp. interactive price chart. Choose custom timeframes to analyze ATNF price movements and trends.
ATNF Company Profile
Discover essential business fundamentals and corporate details for 180 Life Sciences Corp. (ATNF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
27 Jun 2017
Employees
4.00
Website
https://180lifesciences.comCEO
Lloyd Blair Jordan
Description
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
ATNF Financial Timeline
Browse a chronological timeline of 180 Life Sciences Corp. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 May 2026
Upcoming earnings on 12 Nov 2025
Earnings released on 23 Jul 2025
EPS came in at -$0.30 .
Earnings released on 15 May 2025
EPS came in at -$0.67 .
Earnings released on 31 Mar 2025
EPS came in at -$13.25 , while revenue for the quarter reached $95.11K .
Earnings released on 14 Nov 2024
EPS came in at -$0.85 .
Earnings released on 12 Aug 2024
EPS came in at $0.01 .
Earnings released on 15 May 2024
EPS came in at -$1.68 .
Earnings released on 25 Mar 2024
EPS came in at -$1.97 surpassing the estimated -$22.80 by +91.36%, while revenue for the quarter reached $166.03K , missing expectations by -99.00%.
Stock split effective on 28 Feb 2024
Shares were split 1 : 19 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 9 Nov 2023
EPS came in at -$2.85 surpassing the estimated -$26.60 by +89.29%.
Earnings released on 15 Aug 2023
EPS came in at -$13.31 surpassing the estimated -$26.60 by +49.96%.
Earnings released on 15 May 2023
EPS came in at -$24.14 surpassing the estimated -$38.00 by +36.47%.
Earnings released on 31 Mar 2023
EPS came in at -$185.16 falling short of the estimated -$41.80 by -342.97%.
Stock split effective on 19 Dec 2022
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 10 Nov 2022
EPS came in at -$26.62 falling short of the estimated $0.20 by -13.41K%.
Earnings released on 9 Aug 2022
EPS came in at $34.22 surpassing the estimated -$2.60 by +1.42K%.
Earnings released on 16 May 2022
EPS came in at $1.00 surpassing the estimated -$2.60 by +138.46%.
Earnings released on 31 Mar 2022
EPS came in at $1.00 surpassing the estimated -$2.60 by +138.46%.
Earnings released on 15 Nov 2021
EPS came in at $87.45 .
Earnings released on 16 Aug 2021
EPS came in at -$283.37 .
Earnings released on 19 Jul 2021
EPS came in at -$220.21 .
Earnings released on 9 Jul 2021
EPS came in at -$136.69 .
Earnings released on 24 Nov 2020
EPS came in at -$18.70 .
ATNF Stock Performance
Access detailed ATNF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.